PMID- 29766812
OWN - NLM
STAT- MEDLINE
DCOM- 20200518
LR  - 20200518
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 17
IP  - 4
DP  - 2019
TI  - Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective 
      Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated 
      by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
PG  - 411-420
LID - 10.2174/1570161116666180515154555 [doi]
AB  - BACKGROUND: We have found that anagliptin, a dipeptidyl peptidase-4 inhibitor 
      (DPP-4) significantly ameliorates arterial stiffness in Type 2 Diabetes Mellitus 
      (T2DM) patients compared with an equivalent hypoglycaemic agent, glimepiride. 
      However, it remains unclear whether switching DPP-4 inhibitors to tofogliflozin, 
      a selective inhibitor of Sodium-Glucose Cotransporter 2 (SGLT2) improves arterial 
      stiffness in T2DM patients. METHODS: Nineteen T2DM patients who had received 
      DPP-4 inhibitors for at least 1 year were enrolled in this study. Clinical 
      parameters and arterial stiffness evaluated by cardio-ankle vascular index (CAVI) 
      were measured at baseline and after 6-months treatment with tofogliflozin. 
      RESULTS: At 6 months after switching to tofogliflozin, CAVI, waist circumference, 
      body weight, body mass index, subcutaneous and visceral fat volume, white blood 
      cell number, fasting plasma insulin, uric acid, aspartate transaminase (AST), 
      gamma-glutamyl transferase (GTP), and advanced glycation end products (AGEs) were 
      significantly reduced, while red blood cell number, haemoglobin, and HbA1c values 
      were increased. When stratified by median values of change in CAVI after 
      switching to tofogliflozin (DeltaCAVI), baseline serum levels of AGEs were 
      significantly higher in the low DeltaCAVI group (high responder) than in the high one 
      (low responder). DeltaAST and DeltaGTP were positively correlated with DeltaCAVI. CONCLUSION: 
      The present study suggests that switching DPP-4 inhibitors to tofogliflozin 
      ameliorates arterial stiffness in T2DM patients partly via improvement of liver 
      function. Baseline serum levels of AGEs may identify patients who improve 
      arterial stiffness more after treatment with tofogliflozin.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Bekki, Munehisa
AU  - Bekki M
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Tahara, Nobuhiro
AU  - Tahara N
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Tahara, Atsuko
AU  - Tahara A
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Igata, Sachiyo
AU  - Igata S
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Honda, Akihiro
AU  - Honda A
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Sugiyama, Yoichi
AU  - Sugiyama Y
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Nakamura, Tomohisa
AU  - Nakamura T
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Sun, Jiahui
AU  - Sun J
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Kumashiro, Yuki
AU  - Kumashiro Y
AD  - Kumashiro Hospital, Kurume, Japan.
FAU - Matsui, Takanori
AU  - Matsui T
AD  - Department of Pathophysiology and Therapeutics of Diabetic Vascular 
      Complications, Kurume University School of Medicine, Kurume, Japan.
FAU - Fukumoto, Yoshihiro
AU  - Fukumoto Y
AD  - Division of Cardiovascular Medicine, Department of Medicine, Kurume University 
      School of Medicine, Kurume, 67 Asahi-machi, Japan.
FAU - Yamagishi, Sho-Ichi
AU  - Yamagishi SI
AD  - Department of Pathophysiology and Therapeutics of Diabetic Vascular 
      Complications, Kurume University School of Medicine, Kurume, Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT02528019
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glucosides)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - P8DD8KX4O4 
      (6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzhydryl Compounds/adverse effects/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - *Cardio Ankle Vascular Index
MH  - Diabetes Mellitus, Type 2/blood/complications/diagnosis/*drug therapy
MH  - Diabetic Angiopathies/diagnosis/etiology/*physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - *Drug Substitution
MH  - Female
MH  - Glucosides/adverse effects/*therapeutic use
MH  - Glycation End Products, Advanced/blood
MH  - Humans
MH  - Japan
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Risk Factors
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vascular Stiffness/*drug effects
OTO - NOTNLM
OT  - Advanced glycation end products
OT  - SGLT2 inhibitor
OT  - arterial stiffness
OT  - cardio-ankle vascular index
OT  - diabetes mellitus
OT  - tofogliflozin.
EDAT- 2018/05/17 06:00
MHDA- 2020/05/19 06:00
CRDT- 2018/05/17 06:00
PHST- 2018/04/04 00:00 [received]
PHST- 2018/05/19 00:00 [revised]
PHST- 2018/06/19 00:00 [accepted]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2018/05/17 06:00 [entrez]
AID - CVP-EPUB-90438 [pii]
AID - 10.2174/1570161116666180515154555 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2019;17(4):411-420. doi: 10.2174/1570161116666180515154555.